AMRX vs SDZNY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMRX and SDZNY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMRX and SDZNY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amneal Pharmaceuticals is a Bridgewater, New Jersey based biopharmaceutical company with a portfolio of roughly 300 complex generic, specialty, and biosimilar medicines that fill more than 160 million prescriptions a year, mostly in the United States. The business runs in three segments: Affordable Medicines (retail generics, injectables, and biosimilars, the largest at roughly 58% of revenue), Specialty (branded neurology and endocrinology treatments including Parkinson's disease and migraine, around 17% of revenue), and AvKARE (distribution to US federal, retail, and institutional customers, roughly 25% of revenue).

Full AMRX guide

Sandoz Group AG makes off-patent medicines: generics, which copy small-molecule drugs once their patents expire, and biosimilars, which are near-copies of complex biologic drugs such as antibodies. It sells about 1,300 medicines, from antibiotics and cough remedies to cancer and immunology treatments, and employs more than 20,000 people. Net sales were $11.1B in 2025. In the first half of 2026 net sales were $5.76B, up 5% at constant currencies: generics brought in $3.89B (67%) and biosimilars $1.88B (33%, up from 29% a year earlier). By region, Europe is the core at $3.13B (54% of first-half sales), followed by International at $1.34B and North America at $1.30B, which was the fastest-growing region at +15% at constant currencies. The ten largest medicines grew 14% combined and made up 35% of sales.

Full SDZNY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMRX drivers: Specialty and biosimilar mix shift; Kashiv BioSciences acquisition.
• SDZNY drivers: Biosimilar growth and the Bio100 plan; North America and the denosumab launch.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amneal carries meaningful leverage, with net debt of roughly $2.5 billion and a net-debt-to-EBITDA ratio near 3.8x, which amplifies both upside and downside and limits financial flexibility. For SDZNY, price erosion is the constant risk in generics.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMRX if you believe its drivers more; SDZNY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMRX and SDZNY guides.

AMRX. Amneal reaffirmed 2026 guidance of roughly $3.05 to $3.15 billion in net revenue and about $740 to $770 million in adjusted EBITDA. The stock has traded on a relatively rich earnings multiple versus generics peers, reflecting expectations for its specialty and biosimilar growth. Enterprise value of roughly $7.7 billion sits well above market cap because of the substantial debt load.

SDZNY. Trailing sales of ~$11.6B (2025's $11.1B, less the first half of 2025, plus the first half of 2026) put the company at a bit over 3 times sales. The gap between core and reported earnings is wide this year: core net income was $750M in the first half against reported net income of $109M, with legal provisions, restructuring and separation costs making up most of the difference. Net debt of $3.55B is modest next to roughly $2.4B of annualized core EBITDA. The dividend of CHF 0.80 per share for 2025, up from CHF 0.60, works out to a yield of a little over 1% before Swiss withholding tax. Margin progress toward the 25% to 27% 2030 target is the main thing the valuation is waiting on.

Headline figures (approximate, July 2026): AMRX shows revenue (ttm) ~$3.0B, q1 2026 net revenue ~$723M (up ~4% YoY), q1 2026 adjusted ebitda ~$202M (up ~19% YoY), 2026 revenue guidance ~$3.05B to $3.15B; SDZNY shows net sales (ttm to june 2026) ~$11.6B, net sales (h1 2026) ~$5.76B (+5% at constant currencies), core ebitda (h1 2026) ~$1.21B (20.9% margin), core diluted eps (h1 2026) ~$1.71 (reported net income ~$109M).

AMRX and SDZNY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMRX and SDZNY exposure against your real portfolio. It is not an investment adviser.